NasdaqGS:PEPGBiotechs
PepGen (PEPG): Assessing Valuation Following Encouraging FREEDOM-DM1 Phase 1 Clinical Update
If you’ve been following PepGen (PEPG), the latest clinical update might have you rethinking your next move. The company just released results from the 15 mg/kg cohort of its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1, showing progress for its investigational candidate, PGN-EDODM1. With plans to expand its trials in the coming quarters, PepGen is clearly pushing its development pipeline forward. News like this often attracts investor attention when positive data is...